New cancer vaccine: great promise in patients with bladder, brain, breast, esophageal, gastrointestinal, hepatocellular, kidney, lung, melanoma, ovarian, prostate, sarcoma and uterine tumors

Roswell Park Cancer Institute held a press conference this morning to announce the development of an investigational cancer vaccine.

Officials from Roswell were on hand to highlight what the vaccine can do. They say the NY-ESO-1 dendritic cell vaccine has the potential to “eradicate cancer cells and prevent disease relapse.”

The new NY-ESO-1 dendritic cell vaccine is expected to show great promise in patients with bladder, brain, breast, esophageal, gastrointestinal, hepatocellular, kidney, lung, melanoma, ovarian, prostate, sarcoma and uterine tumors.

Not only will the vaccine be administered here in Buffalo, but it will also be manufactured here. Doctors say the development of the vaccine is very encouraging and it has minimal side effects.

The NY-ESO-1 vaccine, tailor-made for each patient, will be produced in RPCI’s Therapeutic Cell Production Facility. http://www.wgrz.com/news/article/152242/37/Roswell-Park-Makes-Major-Annoucement-on-Cancer-Vaccine

Original: http://www.roswellpark.org/media/news/roswell-park-launches-landmark-immunotherapy-vaccine-trial

The purpose of this study is to test the safety of a treatment called DC205 NY ESO 1 vaccine, given with and without sirolimus, and to see what effects (good or bad) it has on you and your type of cancer.

Eligibility

Inclusion Criteria:
Patients with solid tumors at high risk of recurrence or with minimal residual disease
Life expectancy > 6 months
No immunodeficiency

Exclusion Criteria:
Clinically significant heart disease
Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available

http://www.roswellpark.org/clinical-trials/list/191511